Press Releases
17 Feb 2023
The approval of Ximluci® in Europe positions Xbrane as a leading global biosimilar developer
14 Feb 2023
Invitation to presentation of Xbrane Biopharma’s Year-end report 2022 on February 17, 2023.
17 Jan 2023
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
11 Nov 2022
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
28 Oct 2022
Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022
26 Oct 2022
Invitation to presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022
18 Oct 2022
Xbrane has carried out a directed share issue raising gross proceeds of approximately SEK 170 million
19 Sep 2022
By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022